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doi:10.1016/j.kjms.2011.10.013Abstract Quality of life (QOL) in methylphenidate treatment-responsive adolescents with
attention deficit/hyperactivity disorder (ADHD) was assessed. Patients were 12- to 18-year-
old adolescents with ADHD (total n Z 45) who had been on methylphenidate treatment for
at least 3 months and were clinically judged to be improved. The self-completed Taiwanese
Quality of Life Questionnaire for Adolescents (TQOLQA) was used, and the resulting measures
were compared between adolescents with ADHD and: (1) community adolescents (n Z 2316);
(2) treatment-responsive adolescents with a chronic medical condition (i.e., adolescents with
leukemia in its first and complete continuous remission for at least 3 years after chemo-
therapy) (n Z 39). Patients’ cognitive profile and their daily executive functioning were also
obtained for analysis. The QOL of the treated adolescents with ADHD was reported to be worse
than that of both the community healthy adolescents and the adolescent leukemia survivors in
the self-reported TQOLQA domain of “psychological well-being”. Treated adolescents with
ADHD still had impaired executive skills in natural, everyday environments, and the scores
for daily executive abilities could predict the QOL measures. Factors besides pharmacotherapy
should be explored to further improve the QOL of medication-treated adolescents with ADHD.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.of Psychiatry, College of Medicine, Kaohsiung Medical University, 100 Shin-Chuan 1st Rd, Kaohsiung
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Attention-deficit hyperactivity disorder (ADHD) is the most
common neuropsychiatric disorder of children, affecting
approximately 5% of the school-age population [1]. It is
characterized by developmentally inappropriate deficits in
attentional performance, impulsivity, and motor restless-
ness or hyperactivity starting in early childhood [2]. It has
been reported that hyperactivity tends to decline in
adolescence and that improvements occur in attention span
and impulse control [3]. However, there are increased
demands in adolescence for autonomy and independence,
hence symptoms may also worsen and cause progressive
functional impairment, including school dysfunction,
problems with peer interaction, family conflict, poor
occupational performance, injuries, antisocial behavior,
traffic violations, and accidents [1]. Recent prospective
longitudinal studies indicate that up to 50% of individuals
with ADHD continue to experience impairment from some
symptoms of the disorder, if not the full syndrome, in
adolescence and early adulthood [4].
Quality of life (QOL) is a multidimensional concept that
encompasses psychological, physical, and social well-being.
QOL instruments may be particularly relevant to research
on the treatment of ADHD because this disorder has a range
of psychosocial outcomes that are not captured by clinical
symptoms alone [5]. Definition of children’s health-related
QOL has been based on function or disabilities, or in terms
of a match between aspirations and experience [6]. Since
children and adolescents do not share adult views about the
cause, etiology and treatment of illness, and they may also
adopt a different time perspective regarding the course of
a disease, we have to take their age and development into
account. Research from developed and developing coun-
tries has demonstrated that parents reported the health-
related QOL of clinic-based samples of ADHD children to
be poorer than that of the control population [7e9]. In one
recent systematic review of the medication effect on the
QOL in ADHD [7], 25 published papers using seven different
QOL measures were identified. Most (n Z 20) of these
studies focused on children and adolescents, and most
investigated a single molecule, atomoxetine (n Z 15), with
relatively few studies investigating methylphenidate
(n Z 5), amphetamines (n Z 4) and manifaxine (n Z 1).
These studies support a positive short-term effect of
medication on the QOL of children, adolescents and adults
with ADHD that mirrors, to some extent, the effects of these
medications on ADHD symptoms, although with smaller
effect sizes. However, the available data are currently
rather limited in scope. For example, almost all studies used
parent- rather than child-reported measures. There clearly
needs to be more studies regarding self-reported QOL in
those with ADHD.
The present study used the self-reported Taiwanese
Quality of Life Questionnaire for Adolescents (TQOLQA) to
assess the quality of life of methylphenidate-treated Taiwa-
nese adolescents with ADHD. TQOLQA is a questionnaire that
covers the important domains for adolescents, fitting the
personal (physical and mental), interpersonal (family
function, intimate friends, and social networks), external
(income and housing), and global (macro environment)spheres [10]. In addition, the adolescent’s performance in
daily executive skills after methylphenidate treatment was
assessed using a parent-reported questionnaire to analyze its
predictive powers in relation to adolescent QOL outcome.Materials and methods
Patients
The ADHD patients were 12- to 18-year-old adolescents
recruited from the outpatient service of the department of
psychiatry of a university-affiliated hospital in Taiwan. To
enter the study, adolescents were required to meet the
following criteria: (1) diagnosis of ADHD on the basis of the
Diagnostic and statistical manual of mental disorders, 4th
edition (DSM-IV-TR) criteria; (2) continuous methylpheni-
date treatment for at least 3 months and improvement
reported subjectively by the adolescent himself or herself;
(3) improvement as rated by the treating physician using
the Clinical Global Impressions-Improvement (CGI-I) scale
targeting the core symptoms of ADHD listed in DSM-IV
criteria; (4) the adolescent was living with his or her
family, and was not in foster care or an institution; and (5)
the adolescent was tested to have a full-scale intelligence
quotient above 70 by the Wechsler Intelligence Scale for
Children-III [11]. The diagnosis of ADHD was made through
the application of multiple data sources including: (1)
clinician interview; (2) clinical observation of the patient’s
behavior; (3) history provided by the parents and results
obtained from the Chinese-language version of the Swan-
son, Nolan and Pelham IV scales (SNAP-IV Teacher and
Parent Rating Scale, parent version) [12]. The scales
completed by the parents or teachers, or both, were
obtained repeatedly in the clinical services, though with
different time intervals among the ADHD cases, and they
contributed to the final decision of the clinician-rated CGI-
I. Adolescents with a comorbid diagnosis of autism spec-
trum disorder were excluded from the study.
Of the 192 adolescents treated in our clinic during the
6-month recruitment period (January to June 2009), 53 were
eligible for study entry. Questionnaires were delivered to
these 53 adolescents and their parents, to be completed at
home. We had specifically asked the parents not to help with
or inspect the adolescent’s reports on the questionnaires.
Forty-five families (84%) mailed back their questionnaires;
hence, the final study cohort included 45 adolescents with
ADHD (36males and 9 femaleswith an average age of 14 years
10 months 2 years 7 months). Clinical information for each
adolescent was extracted from hospital records and included
both disease-related variables (e.g., ADHD subtype, age at
diagnosis, intelligence quotients, comorbidity pattern) and
treatment-related variables (e.g., age at starting medica-
tion, duration of pharmacological treatment, daily medica-
tion dosage).
In order to compare QOL between hospital and
community samples, as well as adolescents with chronic
medical versus psychiatric conditions, two groups of
controls were enlisted. The first group consisted of
adolescents in the community, and was drawn from the
data bank of the validation study of the Taiwanese Quality
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2316 control adolescents was reported to be free of any
acute or chronic illness, and was sex-matched in ratio to
our case group (1910 boys, 415 girls, with an average age of
12 years 2 months  10 months). The second control group
was a group of adolescents with a chronic medical condition
(leukemia in its first and complete continuous remission for
at least 3 years after chemotherapy). Adolescents with
a pre-existing psychiatric disorder before receiving the
diagnosis of leukemia were excluded. This second group of
39 control adolescents consisted of 26 boys and 13 girls with
an average age of 14 years 5 months  2 years 5 months.
This study was approved by the Institutional Review
Board. Informed consent was obtained from the partici-
pants’ parents following the guidelines of the Institutional
Committee on Clinical Investigation.
Measures
We used the Taiwanese Quality of Life Questionnaire for
Adolescents (TQOLQA), and the Behavior Rating Inventory
of Executive Function (BRIEF), a behavioral rating measure.
TQOLQA is a revised version of the Quality of Life
Questionnaire for Adolescents developed in China on the
basis of the QOL project of the World Health Organization.
The initial 90-item questionnaire was shortened to 38 items
by means of principal component analyses so that a suffi-
ciently short instrument could be used in clinical settings
[10]. The TQOLQA assesses seven factors: family, residen-
tial environment, personal competence, social relation-
ships, physical appearance, psychological well-being, and
discomfort/pain. The questionnaire used a five-point Likert
scale rating and enquired as to the respondent’s experi-
ences over the preceding 2 weeks. Higher QOLOA scores
reflected a better QOL.
BRIEF is a behavioral rating measure that was specifically
designed to assess everyday executive skills in natural,
everyday environments, including the home and school of
the children and adolescents [13,14]. The BRIEF is
composed of two major index scales and a composite of the
two: the behavioral regulation index (BRI), the meta-
cognition index (MI), and the global executive composite
(GEC). Each of the two major index scales is further
composed of subscales. The BRI is composed of the scales
inhibit, shift, and emotional control, and the MI comprises
the scales initiate, working memory, plan/organize, orga-
nization of materials, and monitor. This scale has been
standardized in the Chinese language with valid psycho-
metric data [15], and we obtained this Chinese-language
version from the publisher. Parents of adolescents with
ADHD were asked to complete the BRIEF at the time of
study entry. T-scores were used as the measure in statis-
tical analysis. These scores are linear transformations of
the raw scale scores, and higher T-scores indicate a greater
degree of executive dysfunction. A T-score at or above 65
was considered to fall within the clinical range.
Analysis
Data from self-reported TQOLQA were compared between
the ADHD group and the two groups of control adolescentsseparately, using independent t tests. Effect sizes were
calculated as the means of the control sample minus the
means of the ADHD sample divided by the standard devia-
tion of the control sample [16]. The effect size of 0.2 is
considered small, 0.5 is moderate, and 0.8 is large [17].
Patients’ cognitive profiles and abilities in daily execu-
tive functioning were analyzed by correlational and
regression analysis to determine their predictive power in
relation to the measures of QOL.
Results
Patient characteristics
Of the ADHD adolescents, 80% were boys and the average
age of initial ADHD diagnosis was 10 years 10 months, while
the average current age was 14 years 10 months. ADHD
adolescents were of normal intelligence with mean full-
scale intelligence quotients of 100.76  10.15 (range 85-
123). However, their performance of daily executive skills
as reported by their parents in the BRIEF was in the
impaired range, with average t scores for the BRI of
65.39  11.57 (range 44e92), average t scores for the MI of
66.37  9.74 (range 47-93), and average t scores for the
GEC of 67.37  10.18 (range 47-94).
In all, 8.9% of the ADHD adolescents had comorbid
oppositional defiant disorder, 13.3% had comorbid mood or
anxiety disorders, and 17.8% had academic problems. Only
46.7% of the adolescents were free of any comorbid
psychiatric disorders. Detailed clinical data for the ADHD
group is presented in Table 1.
Self-reported TQOLQA
Group comparisons of adolescents’ self-reports on the
TQOLQA showed that the ADHD adolescents’ QOL was
significantly poorer than that of the community controls in
the domains of “Psychological well-being” (p Z 0.001) and
“Pain/discomfort” (p Z 0.001). In addition, data showed
ADHD adolescents’ QOL to be significantly poorer than that
of the adolescent leukemia survivors in the domains of
“Psychological well-being” (p < 0.05) and “Personal
Competence” (p < 0.05). A detailed presentation of the
comparison of TQOLQA between the ADHD adolescents and
the control groups is presented in Table 2.
Predictors of QOL
Analysis revealed that the domain of “Psychological well-
being” in the TQOLQA of ADHD adolescents was correlated
with the three composite scores of the BRIEF as completed
by their parents (r ranged from e0.38 to e0.78). Regres-
sion analysis was further performed to investigate how the
impairment in daily executive skills might predict QOL
measurements. In summary, performance of daily execu-
tive functions as reflected in the BRI, MI and GEC could
predict the “Psychological well-being” score in the
TQOLQA (all p < 0.01). Poor daily executive skills as
reported by the parents led to poor self-reported measures
on QOL. The results of the regression analysis are pre-
sented in Table 3.
Table 1 Demographic and clinical characteristics of the
children with medication-treated attention deficit/hyper-
activity disorder (ADHD) (n Z 45).
Characteristics
Sex
Male 36 (80.0)
Female 9 (20.0)
Current diagnosis
ADHD, primary inattentive 26 (58.0)
ADHD, combined 19 (42.0)
Current age (yr) 14.82  2.62
Age at diagnosis (yr) 10.80  3.16
Regular medication prescribed since
Grade 1e2 14 (31.1%)
Grade 3e4 7 (15.6%)
Grade 5e6 or after 24 (53.3%)
Comorbidity
Oppositional defiant disorder 4 (8.9%)
Mood disorder/anxiety disorder 6 (13.3%)
Tourette/tic 4 (8.9%)
Developmental language disorder 4 (8.9%)
Academic problems 8 (17.8%)
No psychiatric comorbidity 21 (46.7%)
Verbal intelligence quotient 101.76  10.97
Performance intelligence quotient 100.86  10.72
Full intelligence quotient 100.76  10.15
BRIEF (t score)a
Behavioral regulation index (BRI) 65.27  11.67
Metacognition index (MI) 66.44  9.84
Global executive composite (GEC) 67.38  10.30
Medication Average dose
Methylphenidate only (n Z 43) 48.3 mg/dayb
Methylphenidate plus
antidepressant (n Z 2)
54 mg/dayb
Data are presented as n (%) or mean  SD.
a BRIEF Z Behavior Rating Inventory of Executive Function;
t scores at or above 65 were considered to fall within the
clinical range.
b Average daily dose in Concerta equivalents.
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This was a preliminary study to assess QOL in
methylphenidate-responsive adolescents with ADHD in
a developing Asian country. As reported, there were
significant impairments in psychosocial domains of self-
reported QOL measures, as compared with community
controls and treated adolescents with chronic and severe
medical disorders.
The disease model of medicine has long assumed that
the elimination of the symptoms of disease is in itself
identical to functional remission; hence reports on treat-
ment outcome for psychiatric disorder (including ADHD)
traditionally have focused on symptom-relief efficacy andmedication safety. Among many indicators, the “CGI-I
scale” and “time to stay on medication in the sense of self-
selection for treatment discontinuation” were two
frequently used outcome measures in psychopharmacology
research [18]. Given that treatment responsiveness as
assessed by these two indices was a condition for entry into
our study, the finding that methylphenidate-responsive
adolescents still have poor QOL is a further reminder that
symptoms and functioning are overlapping, but not iden-
tical, constructs in ADHD. As medicine has moved from
a ‘‘life-preserving’’ to a “health-promoting’’ science, QOL
has become one of the important outcome measures in
both clinical research and routine patient care [19]; this is
especially so for psychiatric treatment programs such as
that for ADHD, since psychopathology tends to persist [20].
Danckaerts and colleagues have performed a systematic
review of 36 studies of QOL in children and young people
with ADHD [21]. This review showed that ADHD has a robust
negative impact on QOL across a broad range of psychoso-
cial, achievement and self-evaluation domains, as reported
by the parents of children with ADHD. Our finding adds
support to these QOL studies in individuals with ADHD and
further supports the idea that the negative impact of ADHD
is a cross-cultural phenomenon.
Our comparative findings between treated adolescents
with ADHD and adolescent leukemia survivors deserve
further discussion. While leukemia therapies are highly
effective, recent longitudinal follow-up studies have shown
excesses of both mortality and morbidity in leukemia
survivors. These morbidities include early death, second
neoplasm, organ dysfunction, impaired growth and devel-
opment, decreased fertility and impaired intellectual
function [22,23]. And these late morbidities have had
a negative impact on adolescents’ health-related QOL, as
reported in developed Western countries [24], as well as in
Taiwan [25]. The fact that medication-treated ADHD
adolescents who were clinically judged to be improved
should have a QOL significantly poorer than the adolescent
leukemia survivors in several domains further reminds us
that ADHD is a serious condition.
The finding that many patients considered to have
responded to treatment do not achieve good health leaves
room for improvement in the management of ADHD. One of
our interesting results is that adolescent performance of
daily executive functioning as measured by the BRIEF is
a factor predicting QOL; this may provide an anchor point
for intervention planning. The current models of ADHD
include dysfunction in executive processes as one impor-
tant pathway for understanding this heterogeneous
disorder [26e28]. A recent meta-analytic review suggests
that executive dysfunctions in ADHD have most often been
observed in measures of response inhibition, vigilance,
working memory, and planning [29], and that these all may
affect the actual functional status of the daily executive
skills of the individual adolescent. The actual concordance
and association between performance-based measures of
executive function (e.g., various neuropsychological tests
performed in the laboratory) and ratings of executive
function processes by parents (e.g., BRIEF) have been
demonstrated in a previous study [30]. Our results implied
that by enhancing daily executive skills through well-
designed psychological interventions, an improvement in
Table 2 Taiwanese Quality of Life Questionnaire (TQOLQA) for adolescents: results when administered in adolescents with
attention-deficit/hyperactivity disorder (ADHD) and two control groups.
Control 1a
n Z 2325
Control 2b
n Z 39
Treated ADHD
n Z 45
Effect size,
control 1
versus ADHD
Effect size,
control 2
versus ADHD
Age (months) 170.25  9.65 173.43  29.64 177.86  31.43
Sex M/F 1910/415 26/13 36/9
Family 64.18  20.33 71.87  22.69 63.70  20.17 0.0 0.4
Residential environment 61.29  18.16 62.42  24.85 63.25  18.79 0.1 0.0
Personal competence 55.79  17.00 63.65  22.07 53.57  18.27 0.1 0.5*
Social relationship 59.26  17.94 61.03  21.83 63.18  21.40 0.2 0.1
Physical appearance 69.39  17.15 73.24  16.5 64.31  25.75 0.3 0.5
Psychological well-being 74.90  16.06 76.28  19.25 66.57  20.52 0.5** 0.5*
Pain/discomfort 77.48  15.31 72.65  18.23 66.73  20.56 0.7** 0.3
*p < 0.05; **p < 0.01 (all levels of significance drawn from independent samples t test).
a Control 1 Z community adolescents.
b Control 2 Z adolescent leukemia survivors.
QOL of adolescents with ADHD 283QOL might be possible. Current studies on QOL have
focused almost exclusively on one treatment modality
(pharmacological), so systematic surveys of the impact of
psychotherapy on QOL, on their own or in multimodal
combinations with medication, will be an approach worthy
of further pursuit.
Our study results should be viewed in the light of the
study’s limitations. First, our sample size was small and we
provided the experience of only one treatment center in
Taiwan; the study was not national or population-based inTable 3 Daily executive skills and cognitive function
predicting quality of life index in adolescents with
attention-deficit/hyperactivity disorder (ADHD).
Self-report TQOLQA Psychological well-being
Parameter estimate p (95% CI)
BRIEF
BRI 0.68 (1.18, 0.19)
p Z 0.008
MI 1.10 (1.65,0.56)
p < 0.001
GEC 0.98 (1.51, 0.44)
p Z 0.001
Wechsler IQ
VIQ 0.42 (0.19, 1.02)
p Z 0.172
PIQ 0.35 (0.28, 0.97)
p Z 0.264
FIQ 0.46 (0.17, 1.10)
p Z 0.148
CI, confidence interval; TQOLQA Z Taiwanese Quality Of Life
Questionnaire For Adolescents; BRI Z behavior regulation
index; BRIEF Z Behavior Rating Inventory of Executive Func-
tion; FIQ Z full-scale intelligence quotient; GEC Z global
executive composite; MI Z metacognition index; PIQ, perfor-
mance intelligence quotient; VIQ Z verbal intelligence
quotient.scope. A single institution does not have a sufficient
number of patients to control for the numerous patient-
specific and therapy-specific variables involved. Multi-
institutional collaboration for detailed analysis in the
future would be needed. Second, it has been reported that
there are several levels of factors associated with a child’s
QOL, which include not only the psychopathology of the
child, but also family/school/social networks. Parents’
views may be influenced by the development of other
children (such as the subjects’ siblings), their own
conceptualization of the illness, and their own mental
health [20]. In the study reported here we did not explore
factors such as family composition, family socio-economic
status, family social contacts, school environment,
teachers’ expectations and perceived social support in
their association with adolescent QOL. These may all be
modulating factors in the final QOL of the treated
adolescent. However, these are issues we are not able to
address with currently available data. Third, since both
improved physician-rated CGI and ADHD symptom
improvement were required conditions for entry into the
study and QOL was our focus in terms of outcome
measures, we collected data only from the adolescents’
perspective. Nevertheless, children and parents do not
necessarily share similar views about the impact of illness,
and the correlation between the child’s self-report and
the proxy report is not necessarily consistent [31,32].
Although self-reporting on QOL is assumed to be the
primary method of collecting subjective information about
well-being, measuring concomitant self-reported QOL and
proxy (parental) reports with one instrument would prob-
ably be considered more appropriate.
In conclusion, our findings provide support that
methylphenidate-treated ADHD adolescents still have
multiple problems in broader health outcomes as repre-
sented by the concept of QOL. This study may serve as
a cross-cultural validation of ADHD as a common concern
for adolescents and families worldwide. It has been
proposed that the main goal of healthcare is to improve
patients’ perceptions of their health and the extent to
which health problems interfere with their QOL [33].
284 P.-C. Yang et al.Therefore there is clearly a need for optimization of
current treatment regimens to help adolescents with ADHD.
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